Evolving Treatment Strategies in High-Risk Neuroblastoma - Episode 8

Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

,

Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.

EP. 1: An Overview of Neuroblastoma
EP. 2: Approaches to Diagnosing Neuroblastoma
EP. 3: Role of CURIE Scores in the Treatment and Management of Neuroblastoma
EP. 4: Current Treatment Paradigm for Newly Diagnosed Neuroblastoma
EP. 5: Differentiating Refractory and Relapsed Neuroblastoma
EP. 6: Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
EP. 7: Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
Now Viewing
EP. 8: Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
EP. 9: Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R
EP. 10: Future Perspectives in the Treatment of Neuroblastoma